Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway
Conditions: Advanced Solid Tumor; RAF Mutation; RAS Mutation; NF1 Mutation; Non-Small Cell Lung Cancer; Pancreatic Ductal Adenocarcinoma; Melanoma; BRAF Gene Mutation; CRAF Gene Mutation Interventions: Drug: DCC-3084 Sponsors: Deciphera Pharmaceuticals LLC Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Genetics | Lung Cancer | Melanoma | Non-Small Cell Lung Cancer | Pancreas | Pancreatic Cancer | Research | Skin Cancer | Study